As a consequence of podo loss, the remaining podo(s) may fail to cover completely the outer surface of the GBM. As a result, parietal epithelial cells of Bowman’s capsule may gain access to bare areas of the GBM, forming adhesion and leading to segmental glomeruloscleosis. There are several causes for podocytopenia, including apoptosis, detachment from the GBM, and the inability or lack of podo(s) to proliferate. Although recent

studies have shown that podo(s) undergo apoptosis in glomerular diseases, the main cause for podocytopenia seems detachment of podo(s) from the underlying GBM. Urinary proteins include both soluble proteins and protein components of solid phase elements learn more of urine. The soluble proteins in urine are derived largely from glomerular filtration and the amounts of soluble protein depend on its concentration in the blood plasma, the function of the glomerular filter and the proximal tubular scavenging system. In contrast, LY2109761 solid phase components of urine typically contain relatively

high density particles consisting chiefly of sloughed epithelial cells, casts and other solid phase components that can be isolated by centrifugation at moderate speed. Our previous studies have shown the presence of detached podo(s) in the urine in human glomerular diseases. As a result, after cell loss, their inability to proliferate prevents the restoration of a normal podo number. Meanwhile, we have revealed that numerous podo vesicles are shed in the supernatant of urine which originate from tip vesiculation of podo microvilli on apical cell surface, and that the urinary shedding of vesicles is dramatically increased in patients Florfenicol with glomerulonephritis compared to normal control. The major goal in the field of urine

proteomics is to identify disease biomarkers in the urine that can provide early diagnosis of kidney diseases, the differential diagnosis among kidney diseases and predict response to therapy. An important challenge of this process is to develop an analytical procedure to reflect the pathological process which occurs in the nephron. In glomerular inflammation the markers of podo injury could be highly desirable since podo(s) are located on the outside of the GBM. Moreover, because of its proximity to the urinary space, pathological events occurring in the apical region of podo should be more easily detectable in urine compared to those occurring in the basal or slit diaphragm regions of podo. Based on our previous studies, now we have two methods to detect podo injury as urine biomarker. 1)  U-podocyte; Basic procedures is the IF of urine sediments to detect the detached podo(s) in the urine. The sediments cytospun are stained with anti-podocalyxin (PCX) antibody by standard IF procedures. It is possible to count the podo number in urine. The detection of urinary podo(s) indicates serious podo injury.